Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 8/20 | 0.38 |
| ▸ | NOS3 | P29474 | 7/20 | 0.38 |
| ▸ | NOS2 | P35228 | 6/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293331 | 0.78 | — | — | |
| SCHEMBL17950341 | 0.75 | — | — | |
| SCHEMBL4057745 | 0.74 | NOS2 (0.46) | NOS2HRH3 | |
| SCHEMBL20772857 | 0.74 | KDM1A (0.31) | — | |
| Hydrochloric Acid SCHEMBL17942045 | 0.74 | TDP1 (0.34) | TAAR1HRH3HRH4 | |
| SCHEMBL8015584 | 0.73 | NOS3 (0.47) | NOS1NOS3NOS2HRH4 | |
| SCHEMBL2810659 | 0.73 | KCNH2 (0.41) | NOS2 | |
| SCHEMBL1072255 | 0.73 | — | — | |
| SCHEMBL4521656 | 0.70 | DAO (0.37) | — | |
| SCHEMBL17239455 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-03-10 | — | — | US | disclosed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | HTR2A 869/4885HTR2C 751/4885HTR2B 1533/4885 |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | HTR2A 4364/4885HTR2C 4076/4885HTR2B 4109/4885 |
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | HTR2A 4364/4885HTR2C 4076/4885HTR2B 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.